Talis Biomedical (NASDAQ:TLIS) Shares Up 77.5% – Time to Buy?

Talis Biomedical Co. (NASDAQ:TLISGet Free Report) was up 77.5% on Friday . The stock traded as high as $2.84 and last traded at $2.84. Approximately 59,306 shares changed hands during trading, an increase of 2,761% from the average daily volume of 2,073 shares. The stock had previously closed at $1.60.

Talis Biomedical Price Performance

The company has a market capitalization of $5.18 million, a P/E ratio of -0.10 and a beta of 1.32. The business has a 50-day moving average of $2.02 and a 200-day moving average of $1.67.

About Talis Biomedical

(Get Free Report)

Talis Biomedical Corp is a molecular diagnostics company that develops point-of-care testing solutions for infectious diseases. The company’s technology leverages sample-to-answer automation to deliver rapid, lab-quality results outside of traditional laboratory settings. Talis Biomedical focuses on simplifying complex molecular assays to enable broader access in clinical laboratories, urgent care facilities and other decentralized testing environments.

The company’s flagship Talis One platform integrates proprietary reagents, single-use test cartridges and a compact analyzer to automate the workflow from extracted sample to result.

See Also

Receive News & Ratings for Talis Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talis Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.